Side Effects Linked In Invokana Lawsuit From Talking The SGLT2 Inhibitor

April 20, 2016 - PRESSADVANTAGE -

TheProductLawyers.com reports on two lawsuits which have been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson), discussing their type-2 diabetes drug Invokana. This drug is a new generation of pharmaceutical diabetes treatment along with several other drugs called SGLT2 inhibitors. The initial plaintiffs who have filed recent lawsuits may be the first of many such actions. A predominant allegation by plaintiffs is that using Invokana caused them to develop the deadly condition of diabetic ketoacidosis in which the body's bloodstream develops a surplus of dangerous acid. Consequences may be fatal.

One of the initial lawsuits filed against Invokana manufacturers took place on December 15th, 2015. This complaint was filed under case number 1:15-cv-00636 in the U.S. District Court for the Southern District of Alabama. Details within the suit state that the plaintiff who began to take Invokana in December 2014 quickly developed diabetic ketoacidosis. This plaintiff claims that the drug's manufacturers failed in their duty of care to adequately inform her of this serious risk and that they have likewise neglected to do so with consumers from all across the nation.

She claims that manufacturer Janssen was negligent in their failure to adequately warn patients about the possible risks and side effects of their drug. She also claims that the company neglected to adequately study such risks, and, after gaining approval from the U.S. Food and Drug Administration to market the drug as a type-2 diabetes medication, then also marketed it "off-label" as a type-1 diabetes treatment. "Off-label" marketing is a term used when a drug manufacturer advertises their drug for uses other than those which have been previously approved by the FDA.

A similar lawsuit was filed by a plaintiff in Philadelphia, Pennsylvania in the Court of Common Pleas. This complaint is listed under case number 15-12-00653 and was filed on December 10, 2015. The plaintiff in this case, a male who commenced using Invokana in November of 2014, alleges that after just 3 months of using the drug, he was diagnosed with diabetic ketoacidosis.

Invokana and diabetic ketoacidosis were also the subjects of a recent safety communication issued by the FDA. The FDA's warning required manufacturer, Janssen Pharmaceuticals to change the product's labelling in order to warn consumers of the risks of ketoacidosis and urinary tract infections.

Diabetic ketoacidosis is an acute, condition. This new warning has created an urgency to generate greater public awareness of possible risks. Ketoacidosis can develop in less than 24-hours and untreated, the patients involved can suddenly slip into comas and die. The FDA is warning that patients taking Invokana should carefully watch for signs and symptoms of ketoacidosis which can include nausea and vomiting, abdominal pain, trouble breathing and fatigue.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

For more information about TheProductLawyers.com, contact the company here:

TheProductLawyers.com
Banville Law
888-478-9711
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023